| Recruiting | Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia NCT06965114 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Assessment of Disease Burden in Hairy Cell Leukemia NCT06781515 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | N/A |
| Recruiting | A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemi NCT06561360 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Not Yet Recruiting | Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients NCT05859932 | Power Life Sciences Inc. | — |
| Recruiting | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas NCT06340737 | Stanford University | Phase 1 |
| Recruiting | Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia NCT04815356 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia NCT05388123 | Scripps Health | Phase 2 |
| Terminated | Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product NCT05645744 | Mustang Bio | — |
| Recruiting | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. NCT04775745 | Newave Pharmaceutical Inc | Phase 1 |
| Unknown | B-cell Chronic Lymphoid Malignancies Markers NCT04952974 | University Hospital, Strasbourg, France | — |
| Recruiting | Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant NCT04322383 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL NCT04324112 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer NCT03739606 | City of Hope Medical Center | Phase 2 |
| Terminated | US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI) NCT04125290 | AstraZeneca | — |
| Active Not Recruiting | Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cel NCT03805932 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated C NCT03410875 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocy NCT03010358 | Alexey Danilov, MD | Phase 1 / Phase 2 |
| Completed | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies NCT02362035 | Acerta Pharma BV | Phase 1 / Phase 2 |
| Terminated | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advance NCT02012231 | Fore Biotherapeutics | Phase 1 |
| Active Not Recruiting | Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia NCT01841723 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease NCT01720758 | HaEmek Medical Center, Israel | — |
| Completed | BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia NCT01711632 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Rituximab in Hairy Cell Leukemia: a Multicenter Retrospective Study NCT02883946 | CHU de Reims | — |
| Active Not Recruiting | Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refrac NCT01059786 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia NCT00924040 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia NCT00923013 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia NCT00586924 | MedImmune LLC | Phase 1 |
| Unknown | Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease NCT00462189 | Cambridge Antibody Technology | Phase 1 |
| Completed | LMB-2 to Treat Hairy Cell Leukemia NCT00321555 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia NCT00412594 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Therapy Optimisation for the Treatment of Hairy Cell Leukemia NCT02131753 | University of Giessen | Phase 2 / Phase 3 |
| Completed | Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With NCT00898079 | Children's Oncology Group | — |
| Completed | A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia NCT00001567 | National Cancer Institute (NCI) | Phase 2 |